Less than 10% of individuals that would benefit from weight-loss injections like Wegovy are able to get them, states the global health agency as it publishes its first advice on the drugs.
With more than one billion people worldwide currently living with obesity, it is advocating for increased and just access to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The latest guidance recognises that obesity is a long-term condition that can be managed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key barriers to broad access to the injections that can assist patients in reducing significant weight, notes the body.
Weight-Loss Drug Shortage
Even in the present best projected case, the supply of these medications could only cover around 100 million people – less than 10% of those who need them, according to the health organization.
The guideline urges countries and companies to increase access, via strategies such as licensing agreements.
The intellectual property rights on a key compound – the main component of a leading brand – is scheduled to end in several countries in 2026.
How Obesity Drugs Operate
These medications replicate a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so individuals reduce food intake.
People commonly start to lose weight after several weeks of commencing the regular doses.
Research points to people may see weight return after a year of halting the treatment, because their typical hunger come back.
To be carrying excess weight elevates your likelihood for developing diseases, like diabetes, heart disease, brain attack, and certain malignancies.
Obesity concerns people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
